184 related articles for article (PubMed ID: 34282496)
21. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.
Lee EC; Kim SH; Shim JR; Park SJ
Liver Transpl; 2018 Jan; 24(1):35-43. PubMed ID: 28885774
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
25. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
26. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Kim HR; Cheon SH; Rha SY; Lee S; Han KH; Chon CY; Lee JD; Sung JS; Chung HC
Asia Pac J Clin Oncol; 2011 Sep; 7(3):258-69. PubMed ID: 21884437
[TBL] [Abstract][Full Text] [Related]
27. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
29. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
30. Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome.
Alnaggar M; Lin M; Mesmar A; Liang S; Qaid A; Xu K; Chen J; Niu L; Yin Z
Cell Physiol Biochem; 2018; 48(5):1882-1893. PubMed ID: 30092590
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation.
Scatton O; Zalinski S; Terris B; Lefevre JH; Casali A; Massault PP; Conti F; Calmus Y; Soubrane O
Liver Transpl; 2008 Jun; 14(6):779-88. PubMed ID: 18508370
[TBL] [Abstract][Full Text] [Related]
32. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
33. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues.
Campsen J; Zimmerman M; Trotter J; Hong J; Freise C; Brown R; Cameron A; Ghobrial M; Kam I; Busuttil R; Saab S; Holt C; Emond J; Stiles J; Lukose T; Chang M; Klintmalm G
Liver Transpl; 2013 Sep; 19(9):1020-9. PubMed ID: 23852663
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy Using Activated Natural Killer Cells Improves Postoperative Neutrophil-to-Lymphocyte Ratio and Long-Term Prognosis of Living Donor Liver Transplant Recipients With Hepatocellular Carcinoma.
Imaoka K; Ohira M; Hattori M; Chogahara I; Sato S; Nakamura M; Bekki T; Sato K; Imaoka Y; Nakano R; Yano T; Sakai H; Kuroda S; Tahara H; Ide K; Kobayashi T; Tanaka Y; Ohdan H
Transplant Proc; 2024 Apr; 56(3):634-639. PubMed ID: 38443302
[TBL] [Abstract][Full Text] [Related]
35. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
37. Donor liver natural killer cells alleviate liver allograft acute rejection in rats.
Yu JD; Long TZ; Li GL; Lv LH; Lin HM; Huang YH; Chen YJ; Wan YL
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):386-92. PubMed ID: 21813387
[TBL] [Abstract][Full Text] [Related]
38. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
Satapathy SK; Das K; Kocak M; Helmick RA; Eason JD; Nair SP; Vanatta JM
Clin Transplant; 2018 May; 32(5):e13246. PubMed ID: 29577449
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?
Sotiropoulos GC; Drühe N; Sgourakis G; Molmenti EP; Beckebaum S; Baba HA; Antoch G; Hilgard P; Radtke A; Saner FH; Nadalin S; Paul A; Malagó M; Broelsch CE; Lang H
Dig Dis Sci; 2009 Oct; 54(10):2264-73. PubMed ID: 19057997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
